BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29479868)

  • 1. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.
    Alonso C; Dutta SW; Mitra N; Landsburg DJ; Zaorsky NG; Grover S; Peterson J; Trifiletti DM
    Cancer Med; 2018 Apr; 7(4):1118-1126. PubMed ID: 29479868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database.
    Wang S; Jia M; Han J; Zhang R; Huang K; Qiao Y; Chen P; Fu Z
    Cancer Med; 2021 Jan; 10(2):540-551. PubMed ID: 33249743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
    Farrell K; McKay P; Leach M
    Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma.
    Odei B; Boothe D; Frandsen J; Poppe MM; Gaffney DK
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):819-824. PubMed ID: 29051078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
    Olszewski AJ; Shrestha R; Cook NM
    Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
    Pinnix CC; Milgrom SA; Cheah CY; Gunther JR; Ludmir EB; Wogan CF; Nastoupil LJ; Neelapu SS; Westin J; Lee HJ; Iyer SP; Steiner RE; Fayad LE; Fowler NH; Wang ML; Samaniego F; Rodriguez MA; Rich AE; Medeiros LJ; Dabaja BS
    Blood Adv; 2019 May; 3(9):1356-1367. PubMed ID: 31036721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
    Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IF-RT alone remains gold standard for stage IA nodular lymphocyte-predominant Hodgkin lymphoma].
    Pilz K; Jentsch C; Krause M
    Strahlenther Onkol; 2016 Jun; 192(6):428-30. PubMed ID: 27194138
    [No Abstract]   [Full Text] [Related]  

  • 12. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
    Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
    Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
    Eichenauer DA; Bühnen I; Kreissl S; Goergen H; Fuchs M; von Tresckow B; Rosenwald A; Klapper W; Hansmann ML; Möller P; Bernd HW; Feller AC; Engert A; Borchmann P; Hartmann S
    Br J Haematol; 2022 Jan; 196(1):99-104. PubMed ID: 34396513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Agbay RLMC; Loghavi S; Zuo Z; Fayad L; Dabaja B; Medeiros LJ; Khoury JD
    Am J Surg Pathol; 2018 Apr; 42(4):492-499. PubMed ID: 29309302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
    Prasad M; Narula G; Chinnaswamy G; Arora B; Shet T; Panjwani P; Sengar M; Laskar S; Khanna N; Banavali S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
    Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
    Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Leuk Lymphoma; 2016 Feb; 57(2):320-327. PubMed ID: 26110882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.